Our research reveals the feasibility of CTGF as a therapeutic target and the effectiveness of anti-CTGF mAb as therapeutic agents, which helps to bring new insights to exploit therapeutic strategies for RA and once again emphasize the importance of CTGF in the pathogenesis of RA. This evidence concerns the gene CCN2 and rheumatoid arthritis.